Cidara Therapeutics Management
Management criteria checks 2/4
Cidara Therapeutics' CEO is Jeff Stein, appointed in Jan 2014, has a tenure of 10.5 years. total yearly compensation is $1.56M, comprised of 38.1% salary and 61.9% bonuses, including company stock and options. directly owns 1.6% of the company’s shares, worth $876.31K. The average tenure of the management team and the board of directors is 3.5 years and 3.5 years respectively.
Key information
Jeff Stein
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 38.1% |
| CEO tenure | 10.5yrs |
| CEO ownership | 1.6% |
| Management average tenure | 3.5yrs |
| Board average tenure | 3.5yrs |
Recent management updates
Recent updates
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth
Sep 28
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop
Apr 17Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year
Mar 25We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely
Mar 14Cidara spikes on $11M milestone payment from partner Mundipharma
Oct 04Cidara begins dosing of antiviral CD388 in trial for preventing influenza
Sep 13Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Aug 09Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts
Dec 17Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic
Aug 17Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?
Aug 04Cidara Therapeutics: Rezafungin Data Could Bring Value
Jul 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$36m |
| Dec 31 2023 | US$2m | US$594k | -US$23m |
| Sep 30 2023 | n/a | n/a | -US$35m |
| Jun 30 2023 | n/a | n/a | -US$15m |
| Mar 31 2023 | n/a | n/a | -US$13m |
| Dec 31 2022 | US$1m | US$566k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$33m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$2m | US$566k | -US$42m |
| Sep 30 2021 | n/a | n/a | -US$47m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$74m |
| Dec 31 2020 | US$1m | US$542k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$47m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$1m | US$526k | -US$41m |
| Sep 30 2019 | n/a | n/a | -US$39m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$69m |
| Dec 31 2018 | US$1m | US$501k | -US$69m |
| Sep 30 2018 | n/a | n/a | -US$70m |
| Jun 30 2018 | n/a | n/a | -US$69m |
| Mar 31 2018 | n/a | n/a | -US$59m |
| Dec 31 2017 | US$2m | US$460k | -US$56m |
Compensation vs Market: Jeff's total compensation ($USD1.56M) is above average for companies of similar size in the US market ($USD697.54K).
Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.
CEO
Jeff Stein (69 yo)
10.5yrs
Tenure
US$1,558,544
Compensation
Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.5yrs | US$1.56m | 1.6% $ 885.0k | |
| Chief Legal Officer | 2.9yrs | US$929.86k | 0.11% $ 62.5k | |
| Chief Medical Officer | 7.8yrs | US$884.09k | 0.24% $ 134.0k | |
| Founder and Chief Strategy Officer | no data | US$613.24k | no data | |
| CFO, Chief Business Officer & Principal Accounting Officer | 2.8yrs | US$683.71k | 0.16% $ 91.4k | |
| Senior Vice President of People & Culture | 3.5yrs | no data | no data | |
| Chief Scientific Officer | 5.3yrs | US$1.39m | 0.15% $ 81.2k | |
| Senior VP of Translational Research & Development | less than a year | no data | no data |
3.5yrs
Average Tenure
51.5yo
Average Age
Experienced Management: CDTX's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 10.5yrs | US$1.56m | 1.6% $ 885.0k | |
| Independent Chairman of the Board | 10.3yrs | US$126.84k | 0.0033% $ 1.8k | |
| Independent Director | 10.3yrs | US$98.84k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$86.84k | 0.00033% $ 183.1 | |
| Independent Director | 3.5yrs | US$82.34k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$91.34k | 0% $ 0 | |
| Member of the Scientific Advisory Board | less than a year | no data | no data | |
| Member of the Scientific Advisory Board | 2.2yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
3.5yrs
Average Tenure
62yo
Average Age
Experienced Board: CDTX's board of directors are considered experienced (3.5 years average tenure).